Align Financial’s Ionis Pharmaceuticals IONS Stock Holding History

Align Financial’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$179	Buy	+4	New	+$227	﹤0.01%	624

Other funds holding IONS

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Nicollet Investment Management Minneapolis, Minnesota $336M AUM 22.24% 1-Year Est. Return

Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Cypress Capital Franklin, Tennessee $377M AUM 11.3% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Frank Rimerman Advisors Palo Alto, California $1.81B AUM 32.96% 1-Year Est. Return

Align Financial's IONS Position: Q3 2026 in Review

Align Financial opened a new position in Ionis Pharmaceuticals (IONS) in Q3 2026: 4 shares worth $179. The stake represents ﹤0.01% of the portfolio and ranks #624 among its holdings.

46 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

Align Financial held 4 shares of Ionis Pharmaceuticals worth $179 as of Q3 2026.
Ionis Pharmaceuticals was a new Align Financial position in Q3 2026.
Ionis Pharmaceuticals made up ﹤0.01% of Align Financial's portfolio in Q3 2026, its #624 holding.
46 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on Align Financial's 13F filing for Q3 2026, filed 16 Oct 2026.